Compare SDA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | LAB |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | China | United States |
| Employees | 544 | 389 |
| Industry | Blank Checks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.2M | 394.3M |
| IPO Year | N/A | 2008 |
| Metric | SDA | LAB |
|---|---|---|
| Price | $0.73 | $0.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $4.75 | $1.35 |
| AVG Volume (30 Days) | 144.0K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $15.55 | $2.63 |
| P/E Ratio | ★ N/A | $3.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.87 |
| 52 Week High | $3.29 | $1.72 |
| Indicator | SDA | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 17.81 | 55.24 |
| Support Level | N/A | $0.92 |
| Resistance Level | $2.18 | $1.02 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 1.39 | 73.27 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.